| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Eli Lilly is experiencing significant growth in product development, particularly with the successful market launch of drugs like Mounjaro and Zepbound. The expanding pipeline, including promising new drugs like retatrutide and recently approved products in the weight-loss sector, positions the company favorably in competitive markets. Strong efficacy results from recent trials for retatrutide further enhance its market potential. However, there are concerns surrounding certain treatments that could impact overall perception and advancement. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at 0.9 is bullish. The market sentiment at 0.3 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. LLY is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for sector is at 0.6, and the negative at -0.3 on 2026-08-12. The forces of Sentiment towards Fundamentals (2), Stock Price Trend (0.9), Option Sentiment (0.8), and Sector Price Trend (0.2) will drive up the price. The forces of Valuation Sentiment (-0.4), Price Level Sentiment (-0.5), and Market Risk Appetite (-0.6) will drive down the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||||
| Date | Attention | Price | StdDev | Price Level | RSI | Hourly RSI | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | 0%(0%) | 1220.55 | 2.58% | 82 | 56 | 55 | 0.49% | 0.09% | 0.9 | -0 | 0.6% | 0.4 | Long | 55% | 2 | -3 |
| 2026-08-11 | 0%(0.1%) | 1214.59 | 2.51% | 81 | 58 | 51 | -1.37% | -0.07% | 1.1 | -0 | 1.3% | 1.2 | Long | 55% | 4.9 | 7 |
| 2026-08-10 | 0%(0.1%) | 1231.41 | 2.4% | 99 | 59 | 80 | 3.89% | 0.29% | 1.5 | 1 | 1.6% | 1.3 | Long | 70% | 4.8 | -1 |
| 2026-08-09 | 0%(0.1%) | 0.2 | 1 | 0.9 | 4.8 | -1 | ||||||||||
| 2026-08-08 | 0%(0.1%) | 0.2 | 1 | 1.1 | 4.6 | -1 | ||||||||||
| 2026-08-07 | 0%(0.1%) | 1185.34 | 2.24% | 63 | 57 | 52 | -0.63% | -0.09% | 0.2 | 0.3 | 1% | 1.2 | Long | 55% | 4.6 | -1 |
| 2026-08-06 | 0%(0.1%) | 1192.8 | 2.24% | 70 | 52 | 61 | 2.06% | 0.06% | 0.4 | 0.8 | 2.5% | 1.2 | Long | 55% | 4.5 | -1 |
| 2026-08-05 | 1%(0.1%) | 1168.77 | 2.4% | 46 | 50 | 61 | 4.72% | 0.05% | -0.5 | 1.2 | 2.3% | 1.1 | Wait | 50% | 4.2 | 6.6 |
| 2026-08-04 | 0%(0%) | 1116.11 | 2.65% | 0 | 42 | 43 | -0.45% | -0.5% | -1.9 | -0.3 | 1.1% | 0.5 | Short | 70% | 2.5 | 4 |
| 2026-08-03 | 0%(0%) | 1121.17 | 2.59% | -2 | 43 | 46 | -2.38% | -0.21% | -1.3 | -0.3 | 1.4% | 0.3 | Wait | 50% | 2.2 | -1 |
| Long is the preferred trading strategy with 55% chance of being right. Improving trend sentiment and positive hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||||
| Analysis | ||
| ● Eli Lilly (LLY) – Equity Research Report Tue. Mar 17, 2026 | ||
| 2026-08-12 17:01:22 The competitive landscape in the obesity drug market influences Eli Lilly's strategy, as it faces pressure from other companies introducing similar products, necessitating legal and marketing maneuvers. |
| 2026-08-12 17:01:22 The approval process for retatrutide poses challenges for Eli Lilly, as the company navigates regulatory hurdles while trying to protect its market interests. |
| 2026-08-12 17:01:22 Eli Lilly's financial performance is bolstered by significant revenue growth from its products, reflecting its overall strong market position and investor confidence. |
| 2026-08-12 17:01:22 Recent trials have showcased promising results for Eli Lilly's retatrutide, suggesting its potential to become a leading product in the obesity market if approved by regulatory bodies. |
| 2026-08-12 17:01:22 Eli Lilly is intensifying its legal efforts by filing multiple lawsuits against companies involved in the illegal sale of its investigational weight-loss drug, retatrutide, highlighting concerns over patient safety and unauthorized distribution. |
| 2026-08-12 15:47:14 The emergence of compounded versions of retatrutide from competitors indicates competitive pressures within the weight-loss drug market. |
| 2026-08-12 15:47:14 The introduction of retatrutide as a new weight-loss drug represents significant product development in the pharmaceutical industry. |
| 2026-08-12 15:47:14 Eli Lilly's lawsuit against pharmacies and peptide vendors highlights the legal challenges faced in safeguarding their product from unauthorized sales. |
| 2026-08-12 11:47:35 The involvement of various vendors in the sale of peptide versions signifies heightened competition in the weight-loss drug market. |
| 2026-08-12 11:47:35 Increased consumer interest in peptides for health benefits suggests a growing trend in alternative weight-loss solutions. |
| 2026-08-12 11:47:35 Eli Lilly's lawsuit against pharmacies indicates concerns over the appropriation and sale of their proprietary weight-loss drug compound. |